Profile data is unavailable for this security.
About the company
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
- Revenue in USD (TTM)2.58bn
- Net income in USD-778.69m
- Incorporated1975
- Employees8.03k
- LocationBio Rad Laboratories Inc1000 ALFRED NOBEL DRHERCULES 94547-1811United StatesUSA
- Phone+1 (510) 724-7000
- Fax+1 (510) 741-5817
- Websitehttps://www.bio-rad.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procept Biorobotics Corp | 199.84m | -100.06m | 5.11bn | 626.00 | -- | 20.42 | -- | 25.55 | -1.95 | -1.95 | 3.89 | 4.63 | 0.5026 | 1.83 | 3.86 | 319,238.00 | -25.16 | -- | -28.58 | -- | 57.39 | -- | -50.07 | -- | 5.07 | -- | 0.1758 | -- | 81.55 | -- | -21.51 | -- | -- | -- |
| Inspire Medical Systems Inc | 755.59m | 33.05m | 5.58bn | 1.01k | 171.11 | 8.01 | 146.81 | 7.38 | 1.09 | 1.09 | 25.15 | 23.25 | 1.05 | 2.46 | 9.37 | 747,372.90 | 4.60 | -11.27 | 5.12 | -12.60 | 84.77 | 84.47 | 4.37 | -13.57 | 6.94 | -- | 0.00 | -- | 53.19 | 65.32 | 52.87 | -- | 148.37 | -- |
| Stevanato Group SpA | 1.15bn | 120.12m | 5.94bn | 5.64k | 43.86 | 3.87 | 29.38 | 5.19 | 0.4473 | 0.4473 | 4.26 | 5.07 | 0.5284 | 2.75 | 2.66 | 203,340.60 | 5.54 | -- | 7.39 | -- | 29.20 | -- | 10.48 | -- | 1.21 | 48.53 | 0.2148 | -- | 10.34 | -- | 1.95 | -- | -- | -- |
| Lantheus Holdings Inc | 1.50bn | 427.61m | 6.07bn | 834.00 | 14.51 | 5.15 | 12.39 | 4.06 | 6.02 | 6.02 | 21.09 | 16.97 | 0.8383 | 8.28 | 5.09 | 1,794,723.00 | 23.95 | 6.69 | 32.76 | 7.73 | 64.78 | 57.56 | 28.57 | 9.02 | 1.56 | -- | 0.324 | 0.00 | 38.65 | 30.44 | 1,063.86 | 51.81 | 35.48 | -- |
| Merit Medical Systems Inc | 1.33bn | 120.04m | 6.12bn | 6.95k | 51.45 | 4.62 | 28.11 | 4.62 | 2.04 | 2.04 | 22.55 | 22.71 | 0.6334 | 2.29 | 7.41 | 190,772.80 | 5.73 | 2.45 | 6.32 | 2.77 | 46.83 | 44.50 | 9.05 | 3.91 | 3.82 | 31.88 | 0.3619 | 0.00 | 9.24 | 7.33 | 26.70 | 15.86 | -11.16 | -- |
| Glaukos Corp | 360.35m | -149.57m | 7.77bn | 907.00 | -- | 11.61 | -- | 21.55 | -2.96 | -2.96 | 7.06 | 12.13 | 0.3843 | 1.69 | 7.53 | 397,295.50 | -15.95 | -8.73 | -17.23 | -9.35 | 76.61 | 74.77 | -41.51 | -28.69 | 4.71 | -311.24 | 0.1591 | -- | 11.26 | 11.66 | -35.75 | -- | 14.44 | -- |
| Repligen Corp | 622.64m | -17.13m | 7.94bn | 1.78k | -- | 3.94 | 154.72 | 12.75 | -0.3079 | -0.3079 | 11.09 | 36.00 | 0.233 | 1.57 | 5.29 | 349,206.40 | -0.6411 | 4.38 | -0.7032 | 5.03 | 50.37 | 55.43 | -2.75 | 15.91 | 8.76 | -- | 0.2055 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| Bruker Corp | 3.24bn | 304.90m | 8.52bn | 9.71k | 27.11 | 4.72 | 18.05 | 2.63 | 2.07 | 2.07 | 21.89 | 11.92 | 0.6527 | 1.51 | 5.73 | 333,913.70 | 6.12 | 8.38 | 8.14 | 11.40 | 49.31 | 49.85 | 9.38 | 11.39 | 0.7085 | 26.83 | 0.5549 | 9.81 | 17.14 | 9.36 | 44.03 | 18.91 | 16.79 | 4.56 |
| Teleflex Inc | 3.03bn | 238.01m | 8.85bn | 14.50k | 37.80 | 1.98 | 17.53 | 2.93 | 5.04 | 5.03 | 64.01 | 96.50 | 0.404 | 2.11 | 6.76 | 208,677.50 | 3.18 | 5.86 | 3.46 | 6.42 | 55.99 | 54.43 | 7.87 | 14.62 | 1.39 | 6.61 | 0.2818 | 15.84 | 6.57 | 3.97 | -1.47 | 12.73 | 2.51 | 0.00 |
| Masimo Corp | 2.04bn | 78.60m | 9.05bn | 3.80k | 116.32 | 6.18 | 52.25 | 4.43 | 1.45 | 1.45 | 37.72 | 27.35 | 0.6715 | 1.77 | 5.52 | 537,526.30 | 2.58 | 8.65 | 3.23 | 10.31 | 50.05 | 57.30 | 3.85 | 12.03 | 1.11 | 2.84 | 0.3456 | 0.00 | 0.6042 | 19.00 | -43.21 | -15.96 | 31.06 | -- |
| Bio Rad Laboratories Inc | 2.58bn | -778.69m | 9.16bn | 8.03k | -- | 1.22 | -- | 3.55 | -27.32 | -27.32 | 90.77 | 267.46 | 0.2294 | 1.49 | 5.61 | 321,321.20 | -6.92 | 9.08 | -7.26 | 9.60 | 54.43 | 55.55 | -30.18 | 41.97 | 4.52 | 0.2612 | 0.1383 | 0.00 | -4.67 | 3.13 | 82.43 | -- | 3.83 | -- |
| Henry Schein, Inc. | 12.50bn | 314.00m | 9.20bn | 25.00k | 30.21 | 2.64 | 15.54 | 0.7359 | 2.44 | 2.44 | 96.89 | 27.99 | 1.22 | 4.77 | 7.73 | 499,960.00 | 2.97 | 6.09 | 4.86 | 10.44 | 31.59 | 30.04 | 2.42 | 4.40 | 0.817 | 6.23 | 0.348 | 0.00 | -2.44 | 5.55 | -22.68 | -0.1456 | 21.27 | -- |
| Penumbra Inc | 1.16bn | 34.55m | 9.23bn | 4.20k | 279.56 | 8.35 | 151.56 | 7.93 | 0.8602 | 0.8602 | 29.71 | 28.78 | 0.7897 | 1.04 | 6.08 | 277,089.50 | 2.34 | 2.32 | 2.61 | 2.61 | 65.70 | 63.90 | 2.97 | 3.17 | 3.25 | -- | 0.0218 | 0.00 | 24.95 | 18.93 | 4,643.16 | 68.60 | 9.64 | -- |
| Solventum Corp | 8.22bn | 720.00m | 12.03bn | 22.01k | 16.72 | 3.77 | 9.51 | 1.46 | 4.16 | 4.16 | 47.45 | 18.48 | 0.5831 | 3.93 | 7.19 | 373,290.30 | 5.11 | -- | 6.03 | -- | 56.38 | -- | 8.76 | -- | 0.8268 | 5.02 | 0.7176 | -- | 0.8241 | -- | 0.2234 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Bio Rad Laboratories Inc's reporting currency: US Dollar USD
42.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.88m | 8.25% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.54m | 6.77% |
| Van Eck Associates Corp.as of 30 Sep 2024 | 1.30m | 5.72% |
| Veritas Asset Management LLPas of 30 Sep 2024 | 1.09m | 4.77% |
| First Eagle Investment Management LLCas of 30 Sep 2024 | 713.00k | 3.13% |
| Select Equity Group LPas of 30 Sep 2024 | 708.45k | 3.11% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 635.92k | 2.79% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 608.05k | 2.67% |
| EARNEST Partners LLCas of 30 Sep 2024 | 605.55k | 2.66% |
| Millennium Management LLCas of 30 Sep 2024 | 583.80k | 2.56% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
